Share This Article:

Successful Management of Sickle Cell Intrahepatic Cholestasis with Combined Use of Exchange Transfusion and Single-Pass Albumin Dialysis: A Case Report

Abstract Full-Text HTML XML Download Download as PDF (Size:266KB) PP. 36-42
DOI: 10.4236/ojbd.2013.31008    3,745 Downloads   6,316 Views   Citations

ABSTRACT

Sickle-cell intrahepatic cholestasis (SCIC) is an uncommon complication of sickle-cell disease (SCD), which can be life-threating if left untreated. We present the case of a 28-year-old man with SCD, who presented with jaundice and abdominal pain, one month after hydroxyurea discontinuation. Laboratory investigation revealed solely increased serum bilirubin, mainly conjugated, and imaging studies revealed choledocholithiasis. The patient unterwent an endoscopic sphincterectomy, but his jaundice deteriorated. Sickle-cell intrahepatic cholestasis was suspected and he received aggressive exchange transfusion therapy in combination with hydroxyurea. The jaundice had no signs of improvement; in fact total bilirubin raised up to 1053.7 μmol/L (61.62 mg/dl). Subsequently, the patient was treated with single-pass albumin dialysis (SPAD), in order to remove the excess bilirubin and protect mainly the brain and liver cells from its toxic effects. His laboratory values started to improve after one-and-a-half months of treatment. For the next two months, exchange transfusions were continued and bilirubin gradually returned to baseline values. The successful response appeared after the combined use of exchange transfusion and SPAD, which is being reported for the first time.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

V. Papadopoulos, A. Karagianni, V. Papageorgiou, M. Topalidou, A. Mpellou, P. Patinakis, F. Girtovitis, D. Pantelidou and A. Kioumi, "Successful Management of Sickle Cell Intrahepatic Cholestasis with Combined Use of Exchange Transfusion and Single-Pass Albumin Dialysis: A Case Report," Open Journal of Blood Diseases, Vol. 3 No. 1, 2013, pp. 36-42. doi: 10.4236/ojbd.2013.31008.

References

[1] D. M. Brunetta, A. C. Silva-Pinto, M. do Carmo Favarin de Macedo, S. C. Bassi, J. V. Piccolo Feliciano, F. B. Ribeiro, et al., “Intrahepatic Cholestasis in Sickle Cell Disease: A Case Report,” Anemia, Vol. 2011, 2011, Article ID: 975731. doi:10.1155/2011/975731
[2] T. W. Sheehy, “Sickle Cell Hepatopathy,” Southern Medical Journal, Vol. 70, No. 5, 1977, pp. 533-538. doi:10.1097/00007611-197705000-00008
[3] S. Banerjee, C. Owen and S. Chopra, “Sickle Cell Hepatopathy,” Hepatology, Vol. 33, No. 5, 2001, pp. 1021-1028. doi:10.1053/jhep.2001.24114
[4] D. B. Costa, R. A. Miksad, M. S. Buff, Y. Wang and B. J. Dezube, “Case of Fatal Sickle Cell Intrahepatic Cholestasis Despite Use of Exchange Transfusion in an AfricanAmerican Patient,” Journal of the National Medical Association, Vol. 98, No. 7, 2006, pp. 1183-1187.
[5] A. Betrosian, M. Balla, G. Kafiri, C. Palamarou and N. Sevastos, “Reversal of Liver Failure in Sickle Cell VasoOcclusive Crisis,” American Journal of Medical Sciences, Vol. 311, No. 6, 1996, pp. 292-295. doi:10.1097/00000441-199606000-00012
[6] S. H. Shao and E. P. Orringer, “Sickle Cell Intrahepatic Cholestasis: Approach to a Difficult Problem,” American Journal of Gastroenterology, Vol. 90, No. 11, 1995, pp. 2048-2050.
[7] S. C. Gilli, I. F. Boin, L. Sergio Leonardi, A. C. Luzo, F. F. Costa and S. T. Saad, “Liver Transplantation in a Patient with S(Beta)O-Thalassemia,” Transplantation, Vol. 74, No. 6, 2002, pp. 896-898. doi:10.1097/00007890-200209270-00030
[8] I. Khurshid, L. Anderson, G. H. Downie and G. S. Pape, “Sickle Cell Disease, Extreme Hyperbilirubinemia, and Pericardial Tamponade: Case Report and Review of the Literature,” Critical Care Medicine, Vol. 30, No. 10, 2002, pp. 2363-2367. doi:10.1097/00003246-200210000-00029
[9] F. M. Klion, M. J. Weiner and F. Schaffner, “Cholestasis in Sickle Cell Anemia,” The American Journal of Medicine, Vol. 37, No. 5, 1964, pp. 829-832. doi:10.1016/0002-9343(64)90031-2
[10] D. M. Owen, J. E. Aldridge and R. B. Thompson, “An Unusual Hepatic Sequela of Sickle Cell Anemia: A Report of Five Cases,” American Journal of Medical Sciences, Vol. 249, No. 2, 1965, pp. 175-185. doi:10.1097/00000441-196502000-00006
[11] N. Zakaria, A. Knisely, B. Portmann, G. Mieli-Vergani, J. Wendon, R. Arya, et al., “Acute Sickle Cell Hepatopathy Represents a Potential Contraindication for Percutaneous Liver Biopsy,” Blood, Vol. 101, No. 1, 2003, pp. 101-103. doi:10.1182/blood-2002-06-1823
[12] H. Ahn, C. S. Li and W. Wang, “Sickle Cell Hepatopathy: Clinical Presentation, Treatment, and Outcome in Pediatric and Adult Patients,” Pediatric Blood & Cancer, Vol. 45, No. 2, 2005, pp. 184-190. doi:10.1002/pbc.20317
[13] G. R. Buchanan and B. E. Glader, “Benign Course of Extreme Hyperbilirubinemia in Sickle Cell Anemia: Analysis of Six Cases,” Journal of Pediatrics, Vol. 91, No. 1, 1977, pp. 21-24. doi:10.1016/S0022-3476(77)80436-8
[14] R. E. Ware, “How I Use Hydroxyurea to Treat Young Patients with Sickle Cell Anemia,” Blood, Vol. 115, No. 26, 2010, pp. 5300-5311. doi:10.1182/blood-2009-04-146852
[15] C. B. Almeida, C. Scheiermann, J. E. Jang, C. Prophete, F. F. Costa, N. Conran, et al., “Hydroxyurea and a cGMPAmplifying Agent Have Immediate Benefits on Acute Vaso-Occlusive Events in Sickle Cell Disease Mice,” Blood, Vol. 120, No. 14, 2012, pp. 2879-2888. doi:10.1182/blood-2012-02-409524
[16] M. H. Steinberg, F. Barton, O. Castro, C. H. Pegelow, S. K. Ballas, A. Kutlar, et al., “Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits up to 9 Years of Treatment,” The Journal of the American Medical Association, Vol. 289, No. 13, 2003, pp. 1645-1651. doi:10.1001/jama.289.13.1645
[17] J. Polson and W. M. Lee, “Aasld Position Paper: The Management of Acute Liver Failure,” Hepatology, Vol. 41, No. 5, 2005, pp. 1179-1197. doi:10.1002/hep.20703
[18] C. G. Child and J. G. Turcotte, “Surgery and Portal Hypretension,” In: C. G. Child, Ed., The Liver and Portal Hypertension, Saunders, Philadelphia, 1964, pp. 50-64.
[19] M. Malinchoc, P. S. Kamath, F. D. Gordon, C. J. Peine, J. Rank and P. C. ter Borg, “A Model to Predict Poor Survival in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunts,” Hepatology, Vol. 31, No. 4, 2000, pp. 864-871. doi:10.1053/he.2000.5852
[20] U. Boonsrirat, K. Tiranathanagul, N. Srisawat, P. Susantitaphong, P. Komolmit, K. Praditpornsilpa, et al., “Effective Bilirubin Reduction by Single-Pass Albumin Dialysis in Liver Failure,” Artificial Organs, Vol. 33, No. 8, 2009, pp. 648-653. doi:10.1111/j.1525-1594.2009.00758.x
[21] A. Kortgen, F. Rauchfuss, M. Gotz, U. Settmacher, M. Bauer and C. Sponholz, “Albumin Dialysis in Liver Failure: Comparison of Molecular Adsorbent Recirculating System and Single Pass Albumin Dialysis—A Retrospective Analysis,” Therapeutic Apheresis and Dialysis, Vol. 13, No. 5, 2009, pp. 419-425. doi:10.1111/j.1744-9987.2009.00760.x
[22] M. Wisniewski, M. Barwina, M. Zajac and J. Sein Anand, “[SPAD—New Possibilities?],” Przeglad Lekarski, Vol. 68, No. 8, 2011, pp. 483-485.

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.